Fresenius Kabi (injectable opioids)(FRE.DE)
HQ DE28% share
pharmaceutical · input
IV Parenteral Nutrition Solutions (TPN Bags)
Sterile multi-chamber bags or compounded IV admixtures providing complete or partial nutritional support (amino acids, glucose, lipid emulsion, electrolytes, vitamins, trace elements) for patients unable to absorb nutrition enterally. Critical for: premature neonates (NICU), ICU patients, oncology patients on mucotoxic chemotherapy, patients with short bowel syndrome or intestinal failure. Market concentration: Fresenius Kabi (Kabiven/Smofkabiven), Baxter (Clinimix), B. Braun (Nutriflex). Chronic shortage risk from lipid emulsion ingredient concentration and sterile fill-finish capacity limits.
0
Source countries
4
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on iv parenteral nutrition solutions (tpn bags) somewhere upstream in their supply chain.
Who makes it
Supplier companies
4 companies produce iv parenteral nutrition solutions (tpn bags).
CJ BIO (CJ CheilJedang)(097950.KS)
HQ KR12% share
CJ BIO, the bioscience division of CJ CheilJedang (Korea); world's largest single L-lysine producer by company; ~15-20% global lysine market share; operates the world's most efficient large-scale fermentation platform; produces from corn-based feedstock in Korea (HQ), Iowa USA, Shenyang China, Liaocheng China, Malaysia, Indonesia, and Brazil; invented high-yield lysine fermentation strains; also the global #1 in tryptophan and a top-5 threonine producer
B. Braun SE
HQ DE
German maker of parenteral nutrition (Nutriflex), IV solutions and infusion systems; one of the big three in PN.
Baxter International Inc.(BAX)
HQ US
Dominant US producer of peritoneal dialysis solutions (Dianeal, Extraneal, Physioneal) and major HD consumables manufacturer. The North Cove, NC facility (flooded by Hurricane Helene, September 2024) produced ~60% of US IV fluids and a critical share of PD solution. Baxter's kidney care business was spun out as Vantive in 2024.